Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy.
Solid tumors are known to recruit new blood vessels to support their growth. Therefore, unique molecules expressed on tumor endothelial cells can function as targets for the antiangiogenic therapy of cancer. Current efforts are focusing on developing therapeutic agents capable of specifically targeting cancer cells and tumor-associated microenvironments including tumor blood vessels. These therapies hold the promise of high efficacy and low toxicity. One recognized strategy for improving the therapeutic effectiveness of conventional chemotherapeutics is to encapsulate anticancer drugs into targeting liposomes that bind to the cell surface receptors expressed on tumor-associated endothelial cells. These anti-angiogenic drug delivery systems could be used to target both tumor blood vessels as well as the tumor cells, themselves. This article reviews the mechanisms and advantages of various present and potential methods using peptide-conjugated liposomes to specifically destroy tumor blood vessels in anticancer therapy.
Wu
Han-Chung
HC
Institute of Cellular and Organismic Biology, Academia Sinica, Taipei 11529, Taiwan.
Chang
De-Kuan
DK
Clin Cancer Res. 2001 Feb;7(2):243-54
11234875
Clin Cancer Res. 2002 Feb;8(2):413-8
11839657
Eur J Cancer. 2007 May;43(8):1242-50
17449238
Am J Pathol. 2009 Dec;175(6):2657-67
19875502
J Clin Oncol. 1995 Jul;13(7):1777-85
7602367
J Clin Oncol. 2006 Jun 1;24(16):2505-12
16636341
Cancer Cell. 2009 Dec 8;16(6):510-20
19962669
Eur J Cancer. 2001 Dec;37 Suppl 9:S15-8
11741769
Clin Cancer Res. 2000 May;6(5):1949-57
10815920
J Control Release. 2000 Mar 1;65(1-2):271-84
10699287
Clin Pharmacokinet. 2003;42(5):419-36
12739982
Br J Cancer. 2003 Jun 16;88(12):1979-86
12799646
EMBO J. 1994 May 1;13(9):2236-43
7514533
J Clin Pharmacol. 1996 Jan;36(1):55-63
8932544
Am J Pathol. 2000 Apr;156(4):1363-80
10751361
Science. 1995 Dec 8;270(5242):1657-60
7502074
Cancer Res. 2004 Nov 15;64(22):8249-55
15548691
PLoS One. 2009;4(1):e4171
19137069
N Engl J Med. 2004 Jun 3;350(23):2335-42
15175435
J Gen Virol. 2003 Oct;84(Pt 10):2771-2779
13679612
Curr Pharm Des. 2004;10(19):2335-43
15279612
Clin Cancer Res. 2002 Apr;8(4):1172-81
11948130
Nat Rev Cancer. 2002 Oct;2(10):750-63
12360278
J Control Release. 2010 Mar 3;142(2):167-73
19861140
Nat Med. 2002 Dec;8(12):1369-75
12415261
Nat Med. 1998 May;4(5):623-6
9585240
Nat Rev Cancer. 2004 Oct;4(10):806-13
15510161
Ann Oncol. 2000 Aug;11(8):1029-33
11038041
J Clin Invest. 2000 Apr;105(8):1045-7
10772648
Nat Biotechnol. 1997 Aug;15(8):772-7
9255793
Cancer Res. 2002 Feb 1;62(3):867-74
11830545
Cancer Res. 1987 Jun 15;47(12):3039-51
3555767
Science. 1998 Jan 16;279(5349):377-80
9430587
Science. 2005 Jan 7;307(5706):58-62
15637262
J Clin Invest. 2000 Apr;105(8):R15-24
10772661
Cancer Res. 1994 Jun 1;54(11):2830-3
8187061
Adv Drug Deliv Rev. 2004 Sep 22;56(11):1649-59
15350294
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
2946403
Science. 1995 Jul 14;269(5221):223-6
7542403
Biochemistry. 1997 Jan 7;36(1):66-75
8993319
J Control Release. 2009 Nov 3;139(3):174-81
19576253
Bioconjug Chem. 1997 Mar-Apr;8(2):111-8
9095350
Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4
1763060
Clin Vaccine Immunol. 2007 Apr;14(4):404-11
17287314
Cancer Res. 2006 Oct 15;66(20):10073-82
17047071
Anal Biochem. 1966 Mar;14(3):328-36
4161471
Science. 2004 Mar 19;303(5665):1818-22
15031496
J Infect Dis. 2004 Aug 15;190(4):797-809
15272409
Cardiovasc Toxicol. 2007;7(2):72-4
17652807
Ann N Y Acad Sci. 1991;618:367-82
2006796
Br J Cancer. 1996 Oct;74(7):1023-9
8855969
Cancer Res. 2000 Feb 1;60(3):722-7
10676659
N Engl J Med. 2007 Jan 11;356(2):115-24
17215529
Nat Med. 2002 Feb;8(2):121-7
11821895
Pharmacol Rev. 1999 Dec;51(4):691-743
10581328
Cancer Res. 2007 Nov 15;67(22):10958-65
18006841
Cancer Res. 2002 Dec 15;62(24):7190-4
12499256
Br J Radiol. 1993 Mar;66(783):181-96
7682469
Cancer Res. 2004 Nov 1;64(21):8002-8
15520208
Cancer Res. 2002 Dec 1;62(23):6938-43
12460910
Clin Cancer Res. 2008 Nov 15;14(22):7320-9
19010847
Cancer Res. 2002 Oct 1;62(19):5476-84
12359756
J Clin Microbiol. 2001 Mar;39(3):977-82
11230414
Nat Med. 2004 Feb;10(2):145-7
14745444
Blood. 1999 Mar 1;93(5):1738-48
10029604
Br J Cancer. 2006 Jun 5;94(11):1615-20
16685267
J Biol Chem. 2009 May 8;284(19):12905-16
19276080
Mol Cancer Ther. 2008 Mar;7(3):579-89
18347144
Nat Rev Cancer. 2006 Sep;6(9):688-701
16900224
Cancer Res. 2001 Jun 15;61(12):4750-5
11406547
Clin Cancer Res. 2008 Mar 1;14(5):1310-6
18316549
Cancer Res. 2003 Nov 1;63(21):7400-9
14612539
Cancer Res. 1998 Mar 15;58(6):1195-201
9515805
Science. 2002 Jun 28;296(5577):2404-7
12089446
Cancer Res. 2000 Apr 1;60(7):1878-86
10766175
J Clin Oncol. 2007 Sep 1;25(25):3892-901
17679727
Science. 1997 Nov 7;278(5340):1125-8
9353194
Ann Oncol. 2004 Mar;15(3):517-25
14998859
Cancer Res. 2000 Dec 15;60(24):6942-9
11156394
Cancer. 1995 Apr 15;75(8):2169-73
7697608
Oncology (Williston Park). 2005 Apr;19(4 Suppl 3):7-16
15934498